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Heart failure is a major health burden, affecting 40 million people globally. One of the main causes of systolic heart failure
is dilated cardiomyopathy (DCM), the leading global indication for heart transplantation. Our understanding of the
genetic basis of both DCM and systolic heart failure has improved in recent years with the application of next-generation
sequencing and genome-wide association studies (GWAS). This has enabled rapid sequencing at scale, leading to
the discovery of many novel rare variants in DCM and of common variants in both systolic heart failure and DCM.
Identifying rare and common genetic variants contributing to systolic heart failure has been challenging given its
diverse and multiple etiologies. DCM, however, although rarer, is a reasonably specific and well-defined condition,
leading to the identification of many rare genetic variants. Truncating variants in titin represent the single largest
genetic cause of DCM. Here, we review the progress and challenges in the detection of rare and common variants in
DCM and systolic heart failure, and the particular challenges in accurate and informed variant interpretation, and in
understanding the effects of these variants. We also discuss how our increasing genetic knowledge is changing clinical
management. Harnessing genetic data and translating it to improve risk stratification and the development of novel
therapeutics represents a major challenge and unmet critical need for patients with heart failure and their families.Background
Heart failure is an umbrella term for a compendium of
patient symptoms and physical-examination findings that
are associated with impaired ventricular function, pre-
dominantly due to left ventricular systolic (contractile)
dysfunction (Fig. 1; Box 1). Heart failure represents a final
common phenotype in response to genetic and/or envir-
onmental insults and is thought to affect approximately
40 million people globally [1].
Conventionally categorized based on the level of ejec-
tion fraction as well as by the underlying cause (Fig. 1),
heart failure is most commonly due to ventricular
impairment following an ischemic insult, notably myo-
cardial infarction followed by muscle necrosis, but is also
seen with chronic myocardial hypo-perfusion.
The cardiomyopathies (intrinsic diseases of heart
muscle), including dilated, hypertrophic and restrictive
forms, can all lead to heart failure, although dilated* Correspondence: stuart.cook@duke-nus.edu.sg
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leading global cause for heart transplantation [2–4].
DCM has an estimated prevalence of approximately
1:250, although this might be overestimated [5]. DCM
can be a subset of systolic heart failure, and, although it
can present with the clinical syndrome of systolic heart
failure, it can also present with arrhythmias or thrombo-
embolic disease or be detected in the asymptomatic
patient. DCM therefore does not equate with systolic
heart failure. DCM is predominantly an imaging diagnosis,
whereas heart failure is a clinical and imaging diagnosis.
Heart failure due to hypertrophic cardiomyopathy
(HCM) has been reviewed elsewhere [6] and is not dis-
cussed in detail here. Likewise, we do not discuss heart
failure with preserved ejection fraction (HFpEF), which
represents the situation whereby a patient has symptoms
and signs of heart failure but ventricular systolic function
is ostensibly normal [7]. Estimates of the contribution of
HFpEF, previously referred to as diastolic heart failure, to
heart failure syndromes range from approximately 20 to
70% of cases, reflecting the difficulties in defining the con-
dition and the diversity of the populations studied [8].
Moreover, HFpEF is a highly heterogeneous disease, and
genetic effects can be expected to be very limited as thele is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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Fig. 1 An overview of heart failure syndromes showing where
dilated cardiomyopathy (DCM) and systolic heart failure fit in relation
to all heart failure syndromes. Heart failure syndromes encompass
clinical symptoms and/or signs of heart failure and evidence of
myocardial dysfunction. This can occur in the setting of reduced
(HFrEF; left ventricular ejection fraction <40%) or preserved (HFpEF; left
ventricular ejection fraction >50%) left ventricular ejection fraction. The
contribution of HFpEF, previously referred to as diastolic heart failure, to
heart failure syndromes ranges from 22 to 73%, reflecting the difficulties
in defining the condition and the diversity of the populations studied
[8]. Recently, a third category of heart failure with mid-range ejection
fraction (HFmrEF; left ventricular ejection fraction 40–49%) has been
identified [8], although it has not yet been encompassed into clinical
studies. The commonest cause of HFrEF is myocardial ischemia. DCM
can be a subset of HFrEF and is the commonest cardiomyopathy (CM)
to cause heart failure syndromes. Although DCM can present with the
clinical syndrome of systolic heart failure, it can also present with
arrhythmias or thrombo-embolic disease or be detected in the
asymptomatic patient. DCM therefore does not equate with systolic
heart failure. DCM is predominantly an imaging diagnosis, whereas
heart failure is a clinical and imaging diagnosis. DCM dilated
cardiomyopathy; Other CMs other cardiomyopathies, including
hypertrophic cardiomyopathy
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onmental triggers, hence HFpEF is not discussed further.
Despite optimal medical therapy, clinical outcomes re-
main poor for patients with heart failure syndromes,
with a 5-year mortality of 20% in DCM [9, 10]. Novel
heart failure therapies beyond devices have recently
emerged, but it is too soon to be able to evaluate their
long-term prognostic benefit [11], and whether current
therapies can be tailored to an individual patient has yet
to be explored in detail [12]. Risk stratification tools in
DCM are limited and largely based on qualitative clinical
data, imaging features, and biochemical markers, many
of which reflect changes observed late in the disease
course. Faced with these difficulties, the ideal risk assess-
ment tool would be one that identifies patients at risk of
heart failure before overt disease at a time when apreventative intervention could be used to avoid disease
onset. Genetics offers one such approach.
There have been major advances in DNA sequencing
technologies over recent years, which have enabled the
widespread application of DNA sequencing of heart
failure cohorts. This has led to a rapid increase in the
number of genes associated with DCM. At an even more
rapid pace, DNA sequencing at scale has been applied in
very large cohorts, such as those included in the Exome
Aggregation Consortium (ExAC) data-set [13] [now
renamed the Genome Aggregation Database (gnomAD)
to reflect the inclusion of genome sequencing data].
Against this background, understanding which genes
and variants are of importance for a patient with DCM,
or indeed an apparently healthy individual, is a challenge
for the clinician.
In this review, we examine the genetic underpinnings
of heart failure syndromes, focusing on systolic heart
failure and DCM. We summarize the advances in rare
and common variant discovery and interpretation in
DCM and systolic heart failure, placing recent discover-
ies in the context of early work. We reflect upon how
these discoveries have changed patient management be-
fore considering what implications these findings hold
for future research and patient care.
The genetic architecture of heart failure
syndromes is complex
The proportion of DCM cases with a familial basis is be-
tween 20 and 30%, although a level as high as 60% has
been suggested [14]. In familial DCM, up to 40% of
cases can have an identifiable genetic basis [5], although
as a more critical evaluation of the genes linked to DCM
continues and genes or variants are discounted, this
percentage might fall [15, 16]. Systolic heart failure is a
catch-all phenotypic diagnosis and can be caused by a
variety of insults ranging from myocardial ischemia to
cardiomyopathy. This lack of specificity limits our
understanding of the contribution of genetic variants to
systolic heart failure.
Rare variants are typically defined as having a minor
allele frequency (MAF) of <1%, although the frequency
cut-offs in the literature vary [17]. In line with current
widely accepted definitions, we define rarity as an allele
frequency of <0.001. However, for evaluation of poten-
tially pathogenic variants, we recommend a disease-
specific cut-off informed by disease prevalence, pene-
trance, and allelic contribution to disease [18, 19]. Rare
variants are identified through next-generation DNA
sequencing approaches such as targeted (panel-based)
sequencing, whole-genome or whole-exome sequencing,
or traditional Sanger capillary-based sequencing.
Common variants are typically defined as having a
MAF of >5%. Common variants are identified by
Box 1. Glossary
Arrhythmogenic right ventricular cardiomyopathy (ARVC)—a heart muscle condition leading to functional impairment of the right
ventricle and arrhythmias.
Desmosome—intercellular junctions of cardiomyocytes.
Dilated cardiomyopathy (DCM)—a heart muscle condition leading to left ventricular dilation and systolic impairment.
Electrocardiogram (ECG)—a non-invasive surface recording of the electrical activity of the heart.
Ejection fraction (EF)—a numeric estimate of cardiac function based on the percentage of blood expelled from the right or left ventricle
per heart beat. Cut-offs for left ventricular ejection fraction (LVEF) can be used to define heart failure syndromes. Normal LVEF is >55%.
Genome-wide association study (GWAS)—an unbiased approach, using regression analysis, to assess for the association between
common polymorphisms and disease status/quantitative trait.
Heart failure—a clinical syndrome of symptoms and signs caused by impaired cardiac function. Predominantly left-sided systolic dysfunction,
but can be right-sided systolic impairment and left-sided diastolic impairment.
Heart failure preserved ejection fraction (HFpEF)—heart failure caused by left ventricular diastolic impairment. Systolic function is
preserved, with ejection fraction >50%. Previously termed diastolic heart failure.
Heart failure reduced ejection fraction (HFrEF)—heart failure caused by left ventricular systolic impairment. Previously termed systolic
heart failure.
Hypertrophic cardiomyopathy (HCM)—a heart muscle condition leading to abnormal thickening (hypertrophy) of the left ventricle.
Left ventricular systolic dysfunction (LVSD)—impaired systolic function/reduced left ventricular ejection fraction. Can occur in the
absence of symptoms. Does not imply one particular etiology.
Logarithm (base 10) of odds (LOD)—a statistical test of genetic linkage. A LOD score of >3 is conventionally considered evidence of linkage.
Sarcomere—the contractile unit of muscle, comprising thick and thin filaments.
Single-nucleotide polymorphism (SNP)—a variation in a single nucleotide in the genome, at a position where variation occurs in >1% of
the population.
Titin gene (TTN)—gene coding for the largest human protein, expressed in cardiac and skeletal muscle; the leading genetic cause of DCM.
Z-disc—marks the lateral borders of the sarcomere, the point at which the thin filaments attach.
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on sub-genome arrays (candidate gene studies) or chips
containing many hundreds of thousands of SNPs that,
together with imputation (a statistical process), provide
genome-wide coverage. These approaches form the basis
of genome-wide association studies (GWAS).
Variable disease phenotyping
As with all genetic studies, careful phenotyping of the con-
dition under investigation is crucial for accurate evaluation
and to avoid confounding effects due to phenotypically
similar, but etiologically distinct, conditions. Heart failure
is particularly challenging as it encompasses heterogeneous
conditions with diverse pathobiologies. DCM, although
more limited in its definition, is not immune to imprecise
phenotyping, depending on the imaging modality used
[20], and has a heterogeneous underlying etiology as well
as diverse forms at the imaging and genetic levels. Accurate
phenotyping is therefore important to distinguish DCM
from other causes of ventricular dysfunction. The study of
heart failure as a whole does, however, permit the study of
a ‘final common pathway’ of myocardial damage common
to cardiomyopathies, ischemia, and toxic insults.Challenges in the interpretation of genetic variants
The interpretation of potentially disease-causing rare
variants is challenging owing to the relatively high fre-
quency of rare benign variation in the population. This
means that an individual variant might be rare (allele
frequency <0.001) but, collectively, variation in a specific
gene is common. For example, healthy individuals ap-
pear to carry many unique (private) variants that do not
cause disease. There is, therefore, a need for robust
population-matched control data to avoid spurious
gene–disease associations. The ExAC data-set of over
60,000 exomes will help to address the pressing need for
greater amounts of control data [13]. Several groups
have shown how ExAC can be leveraged to aid the inter-
pretation of rare variants in cardiomyopathies [15, 16].
These population data should be placed, however, in the
context of other available resources to aid clinicians and
researchers in interpreting rare variants, such as disease
variant databases (for example, Human Gene Mutation
Database [21] and ClinVar [22]), computational data (such
as in silico missense variant prediction tools, many of
which are amalgamated in the dbNSFP [23]), functional
data, and, crucially, segregation data. Conflict can arise
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variants being categorized as of ‘uncertain significance’
instead of ‘likely pathogenic’ or ‘pathogenic’. We direct
the reader to the recent American College of Medical
Genetics and Genomics report that provides comprehen-
sive guidelines on variant interpretation [24].
Genetic variants affecting systolic heart failure
In this section, we review advances in the genetics of sys-
tolic heart failure, beginning with a brief discussion of why
discovery of rare variants in systolic heart failure has been
limited, then moving on to a brief summary of candidate
gene studies that underpinned the early discovery work in
this field, before focusing on the advances yielded from
the study of common variants in systolic heart failure
using GWAS.
Rare variants
Heart failure has a heritable component, estimated at
18% based on analyses of the Framingham data-set [25].
However, excluding the monogenic cardiomyopathies
that are due to very rare, private or novel alleles, the
contribution of rare variants (allele frequencies <0.001)
to the risk of systolic heart failure is likely limited and
has yet to be shown conclusively. This is because, as
highlighted above, the etiology of systolic heart failure is
complex and each associated condition might have its
own genetic basis (for example, hypertension and dia-
betes), making it hard to distinguish primary from
secondary effects [26]. Genes that are linked to primary
cardiomyopathies might play little or no role in common
heart failure, but could serve to highlight molecular
pathways that are important for heart failure syndromes
more generically [27].
Candidate gene studies
Many of the published genetic studies of heart failure have
been candidate gene studies for genes involved in the ad-
renergic and renin-angiotensin-aldosterone pathways that
are important for heart failure pathobiology. However, the
most promising associations suggested by the early
candidate gene studies are now no longer thought to be
informative. For example, a meta-analysis of 17 case-
control studies assessing the angiotensin-converting en-
zyme insertion/deletion polymorphism (ACE I/D) found
no association with heart failure [28]. Similarly, a meta-
analysis of 27 studies evaluating the link between common
beta 1 adrenergic receptor polymorphisms (Ser49Gly and
Arg389Gly) and heart failure, first reported in 2000 [29]
and 2003 [30], found that neither was an independent
predictor of prognosis in heart failure [31]. Candidate gene
methodologies have now largely been replaced by the
unbiased approach of GWAS.Common variants
The study of common variants in systolic heart failure
has had some success. Table 1 highlights two studies of
common variants associated with heart failure that are
specific to the heart failure phenotype. Here, we discuss
GWAS approaches to identify variants associated with
potential biomarkers and phenotypes associated with
heart failure, and examine how further studies of the
identified variants can provide insights.
One of the first GWAS of heart failure was carried out
by the CHARGE (Cohorts for Heart and Aging Research
in Genomic Epidemiology) consortium [32]. In this meta-
analysis of four large community-based cohort studies,
almost 25,000 individuals were followed up for a mean of
11.5 years for the development of incident (new onset)
heart failure. This study identified two loci, one that was
near to the gene USP3 (encoding ubiquitin-specific pep-
tidase 3) in individuals of European ancestry, and one near
to the gene LRIG3 (encoding leucine-rich repeats and
immunoglobulin-like domains 3) in individuals of African
ancestry. These findings have yet to be replicated and as
such their importance has yet to be clarified.
Evaluations of a quantitative marker of heart failure
severity or an endophenotype associated with heart
failure, both described below, are alternative approaches
to the study of systolic heart failure, and might mitigate
some of the limitations of imprecise phenotyping of
‘heart failure’ per se.
Cardiac hypertrophy is a common end-result of heart
failure but is a very complex phenotype. One GWAS
identified a SNP associated with cardiac hypertrophy
(rs2207418, P = 8 × 10–6) that was then studied in a heart
failure case-control cohort and was found to associate
with both heart failure and heart failure mortality [33].
This SNP is located in a gene desert on chromosome 20,
although near a highly conserved region. The implica-
tions are that this region might be biologically import-
ant, but the mechanism of action is yet to be established.
Levels of N-terminal pro-brain natriuretic peptide
(NT-proBNP) increase with myocardial wall stress and
are associated with heart failure. A quantitative GWAS
of NT-proBNP levels was performed, although this was
measured in the general population and not a heart
failure population [34], and it is worth noting that
NT-proBNP levels might equally be regulated by genetic
factors unrelated to heart failure. From a discovery cohort
of 1325 individuals and a replication cohort of 1746 individ-
uals, the CLCN6 gene was independently associated with
NT-proBNP levels (rs 1023252, P = 3.7 × 10–8). CLCN6 en-
codes a voltage-gated chloride channel. Indeed, CLCN6
might not be mechanistically implicated in heart failure at
all but instead it might modify expression of NPPB (the
gene encoding BNP) in trans, or might directly regulate
NPPB in cis given the strong linkage disequilibrium (LD)
Table 1 Summary of genome-wide association studies for heart failure and dilated cardiomyopathy
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aFor heart failure, the table focuses on the two main heart failure-specific studies with the strongest evidence. Refer to the main text for discussion of studies
evaluating cardiac endophenotypes, quantitative proxy markers, or subgenome array studies
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of this GWAS, identifying the CLCN6 gene and its possible
interaction with NPPB, have clear mechanistic implications
for the study of the pathogenesis of systolic heart failure.
Other GWAS have evaluated the association between
common variants and cardiovascular endophenotypes of
left ventricular dimensions, function, and mass assessed by
echocardiography or cardiac magnetic resonance imaging
(MRI). The largest of these focussed on an African-
American population of 6765 individuals derived from four
community-based cohorts [35]. The study identified four
genetic loci at genome-wide significance (4.0 × 10−7) that
were associated with cardiac structure and function. SNP
rs4552931 (P = 1.43 × 10−7) was associated with left ven-
tricular mass. The nearest gene is UBE2V2 (which encodes
ubiquitin-conjugating enzyme E2 variant 2), involved in
protein degradation. An intronic SNP on chromosome 10
was associated with interventricular septal wall thickness
(rs1571099, P = 2.57 × 10−8), and an intergenic SNP on
chromosome 17 was associated with left ventricular
internal diastolic diameter (rs7213314, P = 1.68 × 10−7).
Finally, rs9530176, near the CHGB gene (encodingchromogranin B), was associated with left ventricular ejec-
tion fraction (P = 4.02 × 10−7). This protein is abundant in
human catecholamine secretory vesicles and might play a
role in modulation of catecholamine secretion. However,
these variants did not replicate in the EchoGEN European
cohort that the authors also investigated [35].
A recent, novel approach to evaluating genetic deter-
minants of myocardial hypertrophy has been to evaluate
electrocardiographic (ECG) proxy markers of hyper-
trophy [36]. The advantages of this are that, compared
with imaging (using echocardiography or cardiac MRI),
ECG is rapidly acquired, systematically quantifiable, and
low cost. In this meta-analysis of over 73,000 individuals,
52 genomic loci were identified as being associated with
ECG markers of hypertrophy (QRS traits; P < 1 × 10–8).
Although a comprehensive evaluation of these loci is be-
yond the scope of this review, it is interesting that, of
these loci, 32 were novel, and in total 67 candidate genes
were identified that were expressed in cardiac tissue and
associated with cardiac abnormalities in model systems.
These loci appeared to play a role in cardiac hyper-
trophy. Further study of these loci is required to locate
Tayal et al. Genome Medicine  (2017) 9:20 Page 6 of 14the causal genes and molecular pathways leading to the
development of cardiac hypertrophy.
One shortcoming of the GWAS approach is that real
genetic associations might not pass stringent genome-
wide corrected significance thresholds. Using a candidate
gene approach to investigate variants that might not pass
this threshold in GWA studies is one way to mitigate
multiple testing effects. For example, a study evaluating
77 SNPs in 30 candidate genes, most linked to inflam-
mation, evaluated a mixed Caucasian heart failure popu-
lation (322 DCM patients, 268 ischemic cardiomyopathy
patients) and found a 600-kb region on chromosome 5
to be associated with cardiomyopathy (combined P =
0.00087) that replicated in two further populations [37].
The authors performed zebrafish studies that revealed
the disruption of three genes (HBEGF, IK, and SRA1) in
this region that led to a phenotype of myocardial con-
tractile dysfunction. The authors sought to challenge the
paradigm that association studies identify a single causal
or susceptibility locus, and instead point to a haplotype
block that is associated with heart failure. A similar, but
expanded, candidate gene study used subgenome ana-
lysis of approximately 50,000 SNPs in approximately
2000 genes linked to cardiovascular disorders. In this
study, two SNPs were associated with advanced heart
failure in the discovery and replication cohorts [38]
(Table 1). Of these, the most significantly associated
SNP for both ischemic and non-ischemic heart failure
was located in an intronic region of the HSPB7 gene.
HSPB7 warrants some further discussion as it has been
identified in studies of both heart failure and DCM [39, 40].
HSPB7 is a member of the small heat-shock protein family,
expressed in cardiac and skeletal muscle, and functions to
stabilize sarcomeric proteins (Box 1). This same locus was
also identified in a GWAS of DCM [41], which could re-
flect either the physiological importance of HSPB7 and/or
the likelihood that DCM patients were a subset of the
heart failure patients. It is important to note, however, that
the original SNP (rs1739843) and subsequent SNPs in
HSPB7 that were associated with heart failure were in-
tronic or synonymous. The CLCNKA gene, encoding the
renal ClC-Ka chloride channel, is in high LD with HSPB7.
A common SNP (rs10927887) in CLCNKA is associated
with both ischemic and non-ischemic heart failure and in-
creased risk of heart failure (odds ratio 1.27 per allele copy)
[42]. In an expression quantitative trait locus (eQTL) study
of DCM, HSPB7 SNPs were associated with expression of
both the HSPB7 and the CLCNKA gene (rs945425,
HSPB7 expression P = 6.1 × 10–57, CLCNKA expression
P = 2.2 × 10–26) [39]. Therefore, the identification of
HSPB7 could reflect the potentially important role of the
heat-shock protein itself (HSPB7), or the importance of
the renal ClC-Ka chloride channel. The latter is particu-
larly interesting as it alludes to a multisystem biology ofheart failure pathogenesis, something that is clinically well
established.
In summary, a number of studies have been performed
to identify and evaluate causal or susceptibility variants in
heart failure syndromes, but as yet no consistent themes
or common pathways are emerging. Susceptibility variants
are located in both cardiac genes (for example, HSPB7)
and non-cardiac genes (for example, the renal chloride
channel CLCNKA). Modulators of catecholamine secre-
tion, cell signaling, and protein degradation have all been
implicated, suggesting complexity of the underlying mech-
anism(s). Studies to date have also demonstrated the limi-
tation of the variable phenotyping that is associated with
the ‘heart failure’ syndrome. There has been increasing
success in studying cardiovascular endophenotypes of the
heart failure syndrome, such as myocardial mass or
biomarker levels, and this might be the most promising
avenue for future advances.
Genetic factors affecting dilated cardiomyopathy
Here, we review advances in our understanding of the
contribution of rare and common variants to DCM. We
focus particularly on rare variants, given the growth in
the number of variant genes implicated in DCM, and
the challenges in interpreting these data. There have
been fewer advances from common variant studies of
DCM, and we summarize briefly two of the major DCM
GWAS.
Rare variants
Rare genetic variants associated with DCM have been
identified in genes involved with a range of diverse
cellular structures and functions, and most notably with
the sarcomere (Table 2). Inheritance of DCM is most
commonly autosomal dominant, although autosomal re-
cessive, X-linked, and mitochondrial inheritance have
also been reported, particularly in pediatric populations
[43]. Approximately 40% of familial DCM is thought to
have a primary monogenic basis [5]. Higher estimates of
sensitivity for genetic testing have been reported (from
46 to 73% in one study [44]), but these estimates are
likely confounded by insufficient control for population
variation in the genes studied. Although variants in over
50 genes have been linked to DCM, the evidence is most
robust for a ‘core disease set’ encompassing the sarco-
meric genes MYH7 (which encodes beta myosin heavy
chain), TNNT2 (which encodes troponin T2), and TTN
(encoding titin) and the gene LMNA encoding a nuclear
envelope protein.
A recent large-scale analysis of rare genetic variation
in cardiomyopathy cases compared with normal popula-
tion variation has also provided insights into the genetics
of DCM. The study tested for an excess of rare variants
in 46 genes sequenced in up to 1315 DCM cases
Table 2 Genes implicated in monogenic dilated cardiomyopathy and their cellular component
Gene Protein Function Estimated contribution in DCM patients
and phenotypic comments
Sarcomeric
MYH7* Myosin-7 (beta myosin heavy chain) Muscle contraction Non-truncating variants: 5%
TNNT2* Troponin T, cardiac muscle (troponin T2) Muscle contraction Non-truncating variants: 3%
TTN*,# Titin Extensible scaffold/molecular spring Truncating variants: 15–25%
TPM1* Tropomyosin alpha-1 chain Muscle contraction <2%
MYBPC3 Myosin-binding protein C, cardiac type Muscle contraction Major hypertrophic cardiomyopathy
gene; purported association with DCM
now less likely in light of population
variation data [16]
TNNC1 Troponin C, slow skeletal and cardiac
muscles
Muscle contraction Mutations also associated with
hypertrophic cardiomyopathy
TNNI3 Troponin I, cardiac muscle Muscle contraction Mutations also associated with
hypertrophic cardiomyopathy
MYL2# Myosin regulatory light chain 2,
ventricular/cardiac muscle isoform
Regulation of myosin ATPase activity Mutations also associated with
hypertrophic cardiomyopathy
FHOD3# FH1/FH2 domain-containing protein 3 Sarcomere organization
Cytoskeleton
DES* Desmin Contractile force transduction <1%
DMD* Dystrophin Contractile force transduction In patients with dystrophinopathies.
X-linked
VCL Vinculin Cell–matrix and cell–cell adhesion
Nuclear envelope
LMNA* Prelamin-A/C Nuclear membrane structure 4%
Mitochondrial
WWTR1 (TAZ) Tafazzin (WW domain-containing
transcription regulator protein 1)
Associated with syndromic DCM
(for example, Barth syndrome). X-linked
Spliceosomal
RBM20 RNA-binding protein 20 Regulates splicing of cardiac genes 2%
Sarcoplasmic reticulum
PLN Cardiac phospholamban Sarcoplasmic reticulum calcium
regulator; inhibits SERCA2a pump
<1%
Linked to an arrhythmogenic phenotype
Desomosomal
DSP* Desmoplakin Desmosomal junction protein Truncating variants: 3%
Linked to arrhythmogenic right and left
ventricular cardiomyopathy
DSC-2# Desmocollin-2 Desmosomal junction protein Linked to arrhythmogenic right and left
ventricular cardiomyopathy
DSG2# Desmoglein-2 Desmosomal junction protein Linked to arrhythmogenic right and left
ventricular cardiomyopathy
PKP2# Plakophilin-2 Desmosomal junction protein Linked to arrhythmogenic right and left
ventricular cardiomyopathy; recent
studies cast doubt on involvement in
DCM
JUP Junction plakoglobin Desmosomal junction protein Linked to arrhythmogenic right and left
ventricular cardiomyopathy
Ion channels
SCN5A Sodium channel protein type 5 subunit
alpha
Sodium channel <2%. Associated with atrial arrhythmias
and conduction disease. Association
with DCM in absence of segregation less
strong in light of population variation
data [16]
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Table 2 Genes implicated in monogenic dilated cardiomyopathy and their cellular component (Continued)
Z-disc
FLNC# Filamin-C Structural integrity of cardiac myocyte;
actin crosslinking protein
–
NEBL Nebulette Z-disc protein –
NEXN Nexilin Encodes a filamentous actin binding
protein
–
CSRP3 Cysteine and glycine-rich protein 3 Mechanical stretch sensing –
TCAP Telethonin Mechanical stretch sensing –
LDB3 Lim domain-binding 3 Z-disc structural integrity Associated with left ventricular
non-compaction phenotypes
CRYAB Alpha-crystallin B chain Heat-shock protein
Other
BAG3# BAG family molecular chaperone
regulator 3
Inhibits apoptosis –
ANKRD1 Ankyrin repeat domain-containing
protein 1
Encodes CARP, a transcription
coinhibitor
<2%
RAF1# RAF proto-oncogene serine/threonine-
protein kinase
MAP3 kinase, part of the Ras–MAPK
signaling cascade
~9% in childhood-onset DCM (one study)
Transcription factors
PRDM16# PR domain zinc finger protein 16 Transcription factor Mutations cause cardiomyopathy in
1p36 deletion syndrome; also linked to
isolated DCM and left ventricular
non-compaction
ZBTB17# Zinc-finger and BTB domain-containing
protein 17
Transcription factor
TBX5# T-box transcription factor TBX5 Transcription factor Associated with congenital heart disease;
also linked to adult-onset DCM
NKX2-5# Homeobox protein Nkx-2.5 Transcription factor Associated with congenital heart disease;
also linked to adult-onset DCM
GATA4# Transcription factor GATA-4 (GATA-binding
protein 4)
Transcription factor Linked to sporadic and familial DCM
TBX20# T-box transcription factor TBX20 Transcription factor Associated with congenital heart disease;
also linked to adult-onset DCM
Table content adapted from Hershberger et al. [5] and Walsh et al. [16]. We have highlighted the genes with the strongest evidence linking them to dilated
cardiomyopathy (DCM; marked with an asterisk) or the most recently identified genes from 2011 onwards (marked with a hash sign). Causes of predominantly
autosomal recessive DCM and older gene associations that have not been replicated have not been included
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Truncating variants in TTN were the most common
DCM rare variant (14.6%) [16]. There was modest, sta-
tistically significant enrichment in only six other genes
(MYH7, LMNA, TNNT2, TPM1, DSP, and TCAP)
(Table 2). Based on available data, RBM20 is also likely
to prove significant (reviewed below) but was not in-
cluded in the published analysis owing to poor coverage
in the ExAC data. Furthermore, sequencing methods
were not uniform, and not all genes were sequenced
across the DCM cohorts included in the study. Even
allowing for this, many genes that have previously been
linked to DCM, including genes routinely sequenced in
clinical practice such as MYBPC3 and MYH6, showed
little or no excess burden in DCM compared with the
reference population. The accompanying Atlas of Car-
diac Genetic Variation web resource [16] summarizesthese data and serves as a useful adjunct to facilitate the
interpretation of rare variants in DCM.
Recent disease–gene associations in DCM
Over the past decade, 47 new genes have been catego-
rized as linked with DCM in the Human Gene Mutation
Database (HGMD). Many of these links have not been
replicated outside of the original reports, and a compre-
hensive review of these is beyond the scope of this
article. A few examples of novel associations are discussed
below, selected for critical evaluation either owing to
robust evidence, novelty, or clinical importance.
BAG3 encodes a heat-shock chaperone protein and
was first linked to DCM in 2011 through the discovery
of a large 8733-bp deletion in exon 4 in seven affected
family members in a three-generation family, which was
absent in 355 controls [45]. Subsequently, coding exons
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sequenced, which identified seven rare variants (one
frameshift, two nonsense, and four missense variants)
that were absent from 355 controls. The authors were
also able to recapitulate the DCM phenotype in a zebrafish
bag3 knockdown model. In separate studies, BAG3 was
linked to DCM through a GWAS, with the discovery of a
non-synonymous SNP in the coding sequence of BAG3 in
DCM cases compared with healthy controls, which is dis-
cussed further below (rs2234962, P = 1.1 × 10–13) [39]. The
authors then performed targeted sequencing in a cohort of
168 unrelated DCM probands and identified six variants
that were also detected in affected relatives, lending further
support to the role of BAG3 as a disease-causing gene.
RBM20 encodes a spliceosome protein that regulates
pre-mRNA splicing for many genes, including TTN [46],
which is why variants in this gene could hold particular
relevance for DCM, either in isolation or in compound
heterozygosity with TTN [47]. RBM20 was initially asso-
ciated with DCM through linkage analysis in two large
families with DCM [48]. The authors sequenced all 14
RBM20 exons in each family member and identified a
heterozygous missense mutation in exon 9 that co-
segregated with disease in all affected individuals, and
that was absent in unaffected relations and 480 ethnic-
ally matched controls. The authors went on to detect
RBM20 missense mutations in exon 9 in six more
families affected with DCM. Since the original link with
DCM [48], subsequent studies found mutations both
within and outside the original RBM20 hotspot in DCM
probands, but the segregation data on these variants is
limited and the control population was modest in size,
meaning that population-level missense variation was
not accounted for in these regions [49, 50]. The associ-
ation of RBM20 and DCM appears most robust for
variants in the original hotspot, and further curation is
needed to understand the significance of variants in
other regions.
The 1p36 deletion syndrome can be associated with
cardiomyopathy, and the PRDM16 gene (which encodes a
transcription factor) has been identified as a possible car-
diomyopathy gene at this locus, linked with a syndromic
cardiomyopathy as well as with adult-onset DCM (in 5
out of 131 individuals with four novel missense variants)
[51]. However, although there might be a role for
PRDM16 in cardiac development, its role as a cardiomy-
opathy gene has subsequently been questioned [52].
ZBTB17 is also encoded on chromosome 1, at the 1p36
locus. A study of cardiac myocytes and a mouse model of
ZBTB17 deletion demonstrated that ZBTB17 is involved in
cardiac myocyte hypertrophy and is essential for cell sur-
vival [53]. The authors also showed that ZBTB17 encodes
a transcription factor (zinc-finger and BTB domain-
containing protein 17) that binds the gene CSRP3, a Z-discprotein, mutations of which are found in both HCM and
DCM. Given the association between CSRP3 and DCM (in
a small cohort with limited segregation data [54], with no
subsequent replication), and this new-found function of
ZBTB17 in binding CSRP3, the authors hypothesized that
ZBTB17 could be a novel gene implicated in DCM.
Many additional transcription factors have also been
linked to DCM in recent years, such as GATA5 [55],
TBX20 [56], TBX5 [57], GATA6 [58], GATA4 [59], and
NKX2-5 [60]. Some of these genes are clearly linked to
congenital heart disease phenotypes. However, many of
the variants with claimed associations with DCM are
missense variants that have been identified within one
relatively small group of DCM patients, with variable
segregation data. Further studies are required to confirm
the link with DCM.
Desmosomal proteins, typically perturbed in arrhythmo-
genic right ventricular dysplasia/cardiomyopathy (ARVD/
ARVC), have also been linked to DCM. The association
has been most robust for DSP, which encodes desmo-
plakin, a desmosomal protein [61], with a strong excess of
truncating variants in DSP in DCM [16]. However, some
of the more recent associations of desmosomal protein
gene variants have limited variant curation and segrega-
tion data, such as PKP2 [62] (which encodes plakophilin
2), and these associations are less clear. One such PKP2
variant (c.419C > T(p.(S140F)), previously linked to DCM
has been shown not to be associated with heart failure
phenotypes [63]. Therefore, of the desmosomal proteins,
DSP variants have the most robust association with DCM.
Filamin-C (encoded by FLNC) is a Z-disc protein (Box 1)
that provides sarcomeric stability. In recent work, two rare
splicing variants in FLNC were detected through whole-
exome sequencing in two Italian families and in one US
family affected with DCM, with all variants co-segregating
with disease [64]. Only one unaffected variant carrier was
identified, but this individual declined further follow-up.
These variants were absent from 1000 Genomes, NHLBI
Go-ESP, and ExAC. The FLNC cardiomyopathy phenotype
was not associated with skeletal muscle involvement in this
cohort, but was associated with arrhythmias and sudden
cardiac death. In the same study, a zebrafish knockdown
model showed a phenotype of cardiac dysfunction, with
defects in the Z-discs and sarcomere disorganization.
Evaluation of FLNC variants in a large (n = 2877) cohort of
patients with inherited cardiac diseases, including DCM,
has shown that the phenotype of individuals with truncat-
ing variants in FLNC is notable for left ventricular dilation,
systolic impairment, ventricular arrhythmias, cardiac fibro-
sis, and sudden cardiac death [65]. Further replication in
DCM-specific cohorts is needed to validate this potentially
prognostically important phenotypic association.
In summary, there have been many novel gene and
variant associations with DCM. Although some appear
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FLNC, BAG3, RBM20), others require further study (for
example, variants in transcription factors). We encour-
age the reader to maintain critical review of variants out-
side of major disease genes and to utilize the variant
interpretation aids we highlight in this article.
Truncating variants in titin
Truncating variants in the titin gene (TTN) represent
the largest genetic cause of DCM, and, unlike many of
the other genes related to DCM, a cardiologist is likely
to encounter a DCM patient with one of these variants.
However, as the interpretation of these variants is nu-
anced, we take the opportunity to discuss these variants in
more detail. Variants in titin were first associated with
DCM in 2002 through the study of two large multigener-
ational families affected with DCM [66]. In the first kin-
dred, linkage analysis identified a disease gene locus
[maximum logarithm of odds (LOD) score 5.0, penetrance
of 70%]. In this study, TTN was chosen as a candidate
gene owing to high levels of cardiac expression and its
established role in muscle assembly and function. A 2-bp
insertion was identified in exon 326 that resulted in a
frameshift mutation generating a premature stop codon,
and this mutation segregated with disease in family mem-
bers. In the second kindred, a non-truncating TTN mis-
sense mutation in a highly conserved region was identified
that also segregated with disease (Trp930Arg).
More recently, next-generation sequencing technolo-
gies have made the study of the giant titin gene (com-
prising 363 exons) possible in large cohorts. This led to
the discovery that truncating variants in TTN (TTNtv)
are found in approximately 15% of unselected DCM
cases and in up to 25% of end-stage DCM cases [67, 68].
As yet, there do not appear to be any clear genotype–
phenotype correlations permitting the phenotypic differ-
entiation of genetic DCM, although one recent study
suggests a milder phenotype associated with TTNtv car-
diomyopathy than with non-TTNtv cardiomyopathy
[69]. However, the findings in this latter study were
driven by a direct comparison with LMNA cardiomyop-
athy, which has a severe and malignant phenotype, and
need to be interpreted with this in mind.
Variant interpretation is complicated by the fact that
TTN undergoes extensive alternative splicing to produce
different protein isoforms, meaning that not all exons are
included in the final processed mRNA transcripts. Allow-
ing for this process, which is quantified by assessing the
percentage spliced in (PSI)—that is, the percentage of final
cardiac transcripts that include a particular exon—appears
to be important for distinguishing variants that are im-
portant for disease. Variants in exons that are included in
the final transcript more than 90% of the time are most
significant for human cardiomyopathy [68]. Insights frominduced pluripotent stem cell (iPSC) work suggest that
the mechanism underlying TTNtv DCM might involve
haploinsufficiency [70] as opposed to a dominant-negative
model. The importance of haploinsufficiency was
highlighted further in two rat models of TTNtv and by
using Ribo-seq (integrated RNA sequencing and ribosome
profiling) analysis of human RNA samples, which demon-
strated haploinsufficiency of the mutant allele [71].
The finding of the importance of compound-
heterozygous variants for severe phenotypes (for example,
TTN and LMNA variants [72]) shows a potential for
modifier genes or additive genetic effects in DCM. This
concept was alluded to in a multi-center study of 639 pa-
tients with sporadic or familial DCM, with the finding of a
38% rate of compound mutations, and up to 44% when
considering patients with TTNtv [44]. However, these
findings must be interpreted with great caution as the
‘yield’ of DCM variants in this study was far higher than in
any previous study, background population variation was
not well accounted for, and there were no matched con-
trols on the same sequencing platform.
Common variants
There have been two notable DCM-specific case-control
GWA studies, and their results are summarized in
Table 1 [39, 73]. In the first of these studies, two SNPs
with significant association to disease were discovered
and replicated [39]. One SNP was located within the
coding sequence of BAG3 (rs2234962, P = 1.1 × 10–13),
and the authors went on to identify rare variants in
BAG3 in a separate cohort of patients with DCM, as
previously outlined. This is an unusual example of a
situation where common and rare variants in the same
gene can be associated with sporadic and monogenic
forms of the disease, respectively. The second SNP was
located within an intron of transcription factor gene
ZBTB17 (rs10927875, 3.6 × 10–7) [32]. ZBTB17 has since
been postulated to be involved in cardiomyopathy in a
mouse model, as discussed above [53]. However, the
genomic region of this second locus contains many
other genes, including heat-shock protein gene HSPB7,
which has been linked to heart failure syndromes mul-
tiple times.
In the second GWAS of DCM, SNPs in the HSPB7
locus had weak association signals (rs1763610, P = 0.002;
and rs4661346, P = 0.024) [73], but, in a separate associ-
ation study of a subset of patients who featured in the
replication stage of this GWAS, a stronger association
was detected (rs1739843, P = 1.06 × 10–6) [41]. Taking
these findings together with the findings of the sub-
genome array studies of heart failure discussed above
[38], a role for HSPB7 in both DCM and heart failure is
suggested. Also, in the second of the GWA studies for
DCM, the most significant associated SNP (rs9262636,
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and class II major histocompatibility complex heavy
chain receptors [73]. This suggests that DCM might
arise in part as a result of a genetically driven inflamma-
tory process.
In summary, these GWAS in DCM identify suscept-
ibility variants in genes with broad cellular functions
(heat-shock proteins and inflammatory pathway recep-
tors). This breadth makes interpretation of these findings
challenging. Below, we discuss the potential translational
implications of these data, and of the other rare and com-
mon variant discoveries in DCM and systolic heart failure.
Translational implications
Heart failure
As discussed above, many recent genetic studies of sys-
tolic heart failure have suggested the involvement of
novel genes and loci. Although no clear new mechanistic
pathways or novel drug targets have emerged from these
studies, one of the most striking findings has been that,
among those genes linked to systolic heart failure, not
all are expressed exclusively within the heart. For ex-
ample, the CLCKNA gene encodes a chloride channel in
the kidney. The cardio–renal axis is well established
clinically, but the identification of a possible genetic
basis in heart failure offers cautious optimism that fur-
ther study might reveal new therapeutic targets.
Dilated cardiomyopathy
With regards to the potential development of novel and/or
stratified therapeutic interventions, the HCM research field
has led with the development of small-molecule inhibitors
to suppress the development of genetic HCM in mice
[74]. In this work, a small molecule (MYK-461) is able to
reduce myocyte contractility, and, when administered to
mice with HCM-causing myosin heavy chain mutations,
suppresses the development of ventricular hypertrophy,
myocyte disarray, and fibrosis, the hallmark features of
HCM. This could mark the beginning of stratified
medicine in HCM with treatment based on sarcomere
mutation status.
Recent genetic advances in DCM have increased our
understanding of DCM by providing new insights into
the molecular mechanisms for disease pathogenesis.
However, one of the key challenges in interpreting this
mass of data will be to understand which genes are
‘causal’ drivers that directly lead to DCM, and which
genes are less directly impactful and function more as
susceptibility genes. Conceptually, it might be possible
to correct the latter, restoring cardiac function.
In terms of correcting the ‘causal’ driver, one key ex-
ample is the study of the DMD gene, encoding dystrophin,
which is associated with X-linked DCM (Table 2) [14].
Like TTN, it is a large gene. The work by Olson andcolleagues in animal models of gene editing to restore
dystrophin expression in muscular dystrophy offers an
insight into what might one day be achieved in DCM [75].
Next-generation sequencing methods have improved
the efficiency and reduced the cost for genetic testing of
diseases, including cardiomyopathies [76]. The increas-
ing understanding of the genetic basis of DCM has
highlighted the importance of considering genetic testing
in all patients with DCM, not just those with a family
history or a particular phenotype.
Although genetic testing can be carried out using
multi-gene panels, in the clinical as opposed to research
environment, we believe that analysis should be re-
stricted to the genes known to be associated with DCM.
One recent study showed that strict variant classification
can facilitate a highly accurate diagnostic yield in DCM,
with a pathogenic/likely pathogenic variant detection
rate of 35.2% (47.6% in familial DCM and 25.6% in spor-
adic DCM) [61]. Even with these restrictions, many vari-
ants of uncertain significance (VUSs) are identified,
particularly in genes with weak evidence linking them to
DCM. In one study of a diagnostic sequencing labora-
tory, increasing the DCM gene panel from 5 to 46 genes
increased the clinical sensitivity from 10 to 37%, but at
the cost of a large increase in the number of VUSs, with
the number of inconclusive cases rising from 4.6 to 51%
[77]. By taking into account the amount of cumulative
population-level rare variation in cardiomyopathy genes,
the Atlas of Cardiac Genetic Variation website [16] is a
resource to inform clinicians about the role of a specific
gene in DCM or the status of an individual variant, aid-
ing the assessment of the likelihood of pathogenicity.
Titin poses great challenges, as curation of variant
pathogenicity depends upon additional information, such
as whether an exon is constitutively expressed [68]. The
fact that approximately 1% of apparently healthy individ-
uals carry potentially pathogenic truncating variants in
TTN highlights that we should currently only be inter-
preting these variants in individuals already known to
have disease. An online resource has been developed to
facilitate interpretation of TTN truncating variants in
DCM patients [16, 68, 78]. This details the exon com-
position of the major TTN transcripts, with details of
the PSI and other structural features for each exon, as
well as the distribution of TTN variants in large pub-
lished studies of cohorts of DCM patients and controls.
The discovery that peripartum cardiomyopathy shares a
genetic etiology with DCM suggests that pregnancy might
act as an environmental modifier to unmask the pheno-
type of TTNtv cardiomyopathy [79]. It has also been dem-
onstrated that truncating variants of TTN are penetrant in
apparently healthy humans, with subtle expressive
changes in cardiac volumes compared with those of con-
trol subjects without TTNtv [71]. Furthermore, it was
Tayal et al. Genome Medicine  (2017) 9:20 Page 12 of 14shown that rats with TTNtv developed impaired cardiac
physiology under cardiac stress [71], providing further evi-
dence of the importance of gene–environment interac-
tions in the development of the TTNtv cardiomyopathy.
According to current expert recommendations, the
primary role of the identification of a disease-associated
genetic variant in patients with DCM (and indeed the
other genetic cardiomyopathies) is to facilitate cascade
screening and the early discharge of relatives who do not
carry the variant in question [80]. For patients with
DCM, conduction disease, and identified LMNA vari-
ants, clinical guidance suggests that an implantable car-
diac defibrillator should be considered in preference to a
conventional pacemaker owing to the identified geno-
type–phenotype correlation of an increased risk of
malignant (potentially life-threatening) arrhythmias and
sudden cardiac death [81].
The expansion of genetic testing is changing the way re-
searchers define the presence of disease, however, and re-
cent European guidelines have taken this into account,
recognising milder, early phenotypes that do not meet
conventional diagnostic criteria for DCM but are likely to
be on the spectrum of genetic DCM [82]. Early genetic
testing (currently through cascade screening) permits the
identification of genotype-positive but phenotype-negative
(‘G+ P–’) individuals. This is most developed in HCM, an
important parallel for future work in DCM. In one study
of G + P– individuals with sarcomeric HCM mutations,
this group of individuals manifested subtle, subclinical dis-
ease [83, 84], showing early markers of the disease and
suggesting potential therapeutic targets.
Conclusions
Advances in the genetics of DCM and systolic heart
failure have highlighted numerous rare variants linked
to DCM and fewer common variants linked to DCM
and systolic heart failure. DCM and heart failure can
be considered to lie at opposite ends of a spectru-
m—at one end DCM, where genetic contributions are
most commonly due to single gene defects, and at the
other end heart failure, a nebulous term encompassing
a final common pathway resulting from a variety of in-
dividually small-effect-size genetic and environmental
insults.
Within common variant discovery, the identification
of systolic heart failure susceptibility variants expressed
in the kidney or affecting inflammatory pathways re-
minds us of the complexity of the genetics of heart fail-
ure, and finding narrow therapeutic targets for such a
global condition will be a key challenge.
Advances in rare variant discovery have been most
notable for DCM, with the increasing identification of
genes linked to DCM. These discoveries have the scope
to provide novel insights into the pathogenesis ofdisease. However, as we broaden the number of genes to
consider for heart failure syndromes, there will be a
large increase in the number of variants of uncertain
significance that are identified. Maintaining carefully
curated disease databases such as ClinVar is a major
undertaking, and it is unlikely that such curation can
keep pace with the rate of sequencing. To help address
some of these challenges, we can draw upon shared
resources such as ExAC (gnomAD) to understand the
background population-level variation, which has previ-
ously confounded the study of rare diseases. Familiarity
with these resources will be essential in navigating the
complex genetic architecture of both DCM and systolic
heart failure in the future.
Genetic advances are informing new approaches for
clinical management of patients with DCM and have
highlighted the importance of considering genetic testing
in all patients with DCM, not just those with a family
history. Challenges remain in establishing clear geno-
type–phenotype correlations and in translating genetic
advances into improvements in patient care for risk
stratification or the development of novel therapies. In
the short term, the field would benefit greatly from stan-
dardized phenotyping of both DCM and systolic heart
failure using imaging and clinical criteria to ensure
parity across studies.Abbreviations
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